Answers are grounded in this paper and cite their sources.
Sera of 2 African patients with Burkitt's lymphoma and 3 with nasopharyngeal carcinoma were examined for antibodies against the EBV-associated membrane antigen complex by titrating their blocking activity against an FITC-conjugated reference immunoglobulin (F-Mutua)derived from a case of Burkitt's lymphoma in long-term remission. The sera were tested beforeat the terminationand 6-9 weeks after applying local radiotherapy to the tumor. Burkitt lymphoma-derivedEBV-carrying lymphoblastoid cell lines were used as target cells. Three patients with other tumors receiving radiotherapy served as controls (a case of Hodgkin's diseaselaryngeal carcinoma and lymphosarcomarespectively). Six to 9 weeks after irradiation of the tumorthere was a significant increase in the titer of membrane-reactive antibodiesin both cases of Burkitt's lymphomaand in all 3 cases of nasopharyngeal carcinomabut not in the “control” tumors.
No takes yet. Share an insight, caveat, or question.
Einhorn et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: